Chlorzoxazone in Hip and Knee Arthroplasty

Osteoarthritis, Knee Clinical Trial

— chlorzoxazon  

Official title:

Analgetic Effects of Chlorzoxazone in Total Hip and Knee Arthroplasty

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02405104
• Other study ID #: ON-151-MU-Klorz
• Status: Completed
• Phase: Phase 4
• Start date: September 1, 2015
• Est. completion date: July 31, 2019

Study information

• Verified date: September 2019
• Source: Northern Orthopaedic Division, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to elucidate whether patients operated with THA and TKA can benefit from treatment with chlorzoxazone.

Description:

Introduction and rationale Background Modern treatment of pain following surgery based on multimodal analgesic strategy where the pain system different points of attack struck with different types analgesics. This also tries to reduce the consumption of opioids associated with frequent side effects like nausea, vomiting, constipation, difficulty urinating, weather stretch problems and Lethargy.

But in spite of intense research over the last decades, is pain after arthroplastic surgery in hip (total hip arthroplasty (THA)) or knee (total knee replacement (TKA)) continue a significant clinical problem. It is a current clinical assumption that patients with pain in the hip or knee region immediately after TKA or THA have tense muscles, which reinforces pain behavior. The mechanism for such muscle tension is not fully understood.

For many years the investigators have been on Danish orthopedic departments dealt with these patients with postoperative pain after major joint prosthesis operations with the muscle relaxant chlorzoxazone. On some sections included in the standard chlorzoxazone prescriptions for pain after hip and knee replacement.

chlorzoxazone has for many years been marketed for the treatment of pain in skeletal muscle by inhibition of mono- and polysynaptic reflexes in the CNS. The muscle relaxing effect is mediated by inhibitory effects on spinal polysynaptic reflexes. In placebo-designed clinical studies of chlorzoxazone's beneficial effect on heterogeneous groups of patients with spasticity, motor neuron syndromes, as well as muscle pain and spasm of peripheral musculoskeletal diseases have not been able to demonstrate no significant analgesic effect; chlorzoxazone have also failed to show pain-relieving effect in the treatment of back pain It is remarkable that in spite of the widespread use of chlorzoxazone not can be found only one study of chlorzoxazone used as adjuvant pain relieving treatment after hip or knee surgery (or other orthopaedic treatment). The current clinical practice is therefore made on purely empirical basis. The effect must be considered as uncertain, but may in some cases be indicated, most often as an adjunct to other therapy, for example analgesics, anti-inflammatory agents, physiotherapy or even training. In such cases, regarded chlorzoxazone be an alternative to benzodiazepines. There is therefore a need for a prospective, randomized, double-blind, placebo-controlled study evaluating the potential analgesic effect of chlorzoxazone. In this intervention study is the selected dosage of chlorzoxazone set at based on the recommendation of the Danish Medicines Information A / S 7 (http://pro.medicin.dk/Medicine / Preparations / 638) and Takeda Pharma A / S. The latter produces chlorzoxazone. The recommendation is based on our current knowledge of chlorzoxazones pharmacodynamic and pharmacokinetic properties. chlorzoxazone given in this study as tablet chlorzoxazone, 250 mg, 3 times daily for the first seven postoperative days. Adverse reactions to chlorzoxazone are well known. They are relatively few, mostly mild and transient. The most frequent adverse events related to chlorzoxazone, fatigue and dizziness (about 1-10% of patients) Adverse reactions are to some extent overlapping with the side effects that are related to the perioperative opioid treatment. It is therefore possible that the frequency of adverse events overall is reduced if chlorzoxazone found to be analgesic (and opioid-sparing). Patients will be hospitalized for a minimum of two nights after surgery and thus be close observation in the period in which the risk of side effects is greatest. At the same time, all patients undergo standardized adverse event registration. If, contrary to expectations unexpected or unacceptable side effects medication will promptly be interrupted. The study involves a group of patients (THA and TKA), which is an important clinical pain problem. All of these patients receive a well-implemented and evidence-based treatment. Thus, anesthesia, analgesia and surgical procedure standardized for all patients receiving concomitant consequences usual principles of early mobilization 8; 9th The planned randomized, double-blind, placebo-controlled design in which all patients receive the same and standardized interventions, enabling the best possible evaluation of modality under study intervention with chlorzoxazone vs. placebo). The level of pain after surgery as the primary endpoint, recorded by means of a well-tested and validated tool (visual analog scale (VAS)) 48 hours after operation. The current study could contribute to a clarification of the postoperative analgesic effect of chlorzoxazone immediately after THA and TKA. As secondary endpoints, the patients functional level be determined Oxford Hip / Knee Score 7 days after surgery. Furthermore, a number of tertiary parameters related to pain, function and side effect profile be determined as shown in Table 1. Evidence in this area will be of immediate benefit to patients operated with THA and TKA - and maybe for other surgical patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: July 31, 2019
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Planned primary unilateral THA or TKA

• Patients (male/female) = 18 år

• Patients giving written informed consent and authority.

• Patients receiving spinal anaesthesia

Exclusion Criteria:

• Patients with intolerance to trial medications

• Rejection of or contraindicated spinal anaesthesia

• Patients with rheumatoid arthritis.

• Patients with Body Mass Index (BMI) = 35

• Patients that do not read or write Danish

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis of Hip
• Osteoarthritis, Hip
• Osteoarthritis, Knee

Intervention

Drug:
• chlorzoxazone
ATC-code: M03BB03
• Placebo
Placebo

Procedure:
• THA
Surgical treatment of osteoarthrosis in the hip, by replacement.
• TKA
Surgical treatment of osteoarthrosis in the knee, by replacement.

Locations

Country	Name	City	State
Denmark	Northern Orthopaedic Division, Clinic Farsø, Aalborg University Hospital	Farsø	Northern Jutland

Sponsors (1)

Lead Sponsor	Collaborator
Northern Orthopaedic Division, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain after 5 meter walk	VAS-score	24 hours post OP
Secondary	Oxford Hip/Knee score	standardized functional and pain score	7 days post OP
Secondary	Pain at rest	VAS	until 12 months after surgery
Secondary	worst pain for the last 24 hours	VAS	until 12 months after surgery